Kemin presents the effect of dietary addition of Bacillus Subtilis PB6 spores on gut health conditions at 2 conferences in France.
Recent news suggests that an increasing number of pathogenic bacteria are developing multi-resistance against antibiotics which can lead to a life threatening situation for humans.
In several European countries, debates are ongoing among industry stakeholders regarding the appropriate industry response to this news.
Managing gut health
The industry must move quickly to adopt new methods for managing gut health and optimizing animal performance.
Gut health issues in poultry often arise, resulting in an overgrowth of Clostridium perfringens that lead to bacterial enteritis. As a result, antibiotics are often fed to help animals cope with Clostridium challenges.
CloStat contains a unique strain of Bacillus subtilis PB6 that has been isolated and selected from the gut of healthy chickens that naturally coped with a Clostridia challenge.
Through a preventive application, the probiotic lowers poultry gut health challenges.
Several field trial reports and testimonials from veterinarians across Europe indicate that CloStat works effectively as a natural solution to maintain a balanced gastro intestinal tract.
Through preventive application in poultry production, several veterinarians have reported improved poultry health and reduced incidences of bacterial enteritis. This has lead to different views how animal health can be supported.
In view of the current challenges, true preventive solutions have to be considered by the poultry industry.
To further inform the market Kemin presents the EU approval process of Bacillus subtilis PB6 at Probiotech in Paris, June 22-23, 2010.
At the European Poultry Conference in Tours, August 10, 2010, Kemin shares the effect of dietary addition of Bacillus Subtilis PB6 spores on gut health conditions in commercial broiler production.